JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: Process and product

Keyphrases

• Cholesterol Guidelines 100%
• Inflammatory Diseases 50%
• Chronic Kidney Disease 50%
• Metabolic Syndrome 50%
• High Risk 50%
• Preeclampsia 50%
• Clinical High Risk 50%
• Non-statins 50%
• Population Groups 50%
• Ultra-high Risk 50%
• High-sensitivity C-reactive Protein (hs-CRP) 50%
• Hypertriglyceridemia 50%
• Finished Product 50%
• Low-density Lipoprotein Cholesterol (LDL-C) 50%
• Cost Value 50%
• Homozygous Familial Hypercholesterolemia (HoFH) 50%
• LDL Cholesterol 50%
• Risk Decision 50%
• Intermediate Risk 50%
• Value Assessment 50%
• Groups at Risk 50%
• Coronary Artery Calcium Score 50%
• Cholesterol Reduction 50%
• Take-home 50%
• Apolipoprotein B (Apo B) 50%
• Premature Menopause 50%
• Lp(a) 50%
• Patient Discussion 50%
• Committee Decisions 50%
• Risk-enhancing Factors 50%

Medicine and Dentistry

• Pre-Eclampsia 100%
• Metabolic Syndrome 100%
• Inflammatory Disorder 100%
• Chronic Kidney Disease 100%
• Low Density Lipoprotein Cholesterol 100%
• Familial Hypercholesterolemia 100%
• Hypertriglyceridemia 100%
• Health Care Cost 100%
• Early Menopause 100%
• Clinician 100%
• Coronary Artery Calcium 100%